What do systematic reviews say?

Intervention not reported

• Oral paracetamol (acetaminophen) for cancer pain 2017 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 93 participants
  Very low

5‐ASA vs placebo

5‐ASA showed no clear difference in relapse, drop‐outs classed as relapse, grouped by length of compared with placebo (moderate certainty).

• Oral 5‐aminosalicylic acid for maintenance of medically‐induced remission in Crohn's disease 2016 · Cochrane Headline outcomes only
  RR 0.98 [0.91, 1.07]
  11 studies · 2014 participants
  Moderate
• Oral 5‐aminosalicylic acid for maintenance of medically‐induced remission in Crohn's disease 2016 · Cochrane Headline outcomes only
  RR 0.99 [0.8, 1.23]
  1 study · 161 participants
  Low
• Oral 5‐aminosalicylic acid for maintenance of medically‐induced remission in Crohn's disease 2016 · Cochrane Headline outcomes only
  RR 1.07 [0.86, 1.33]
  1 study · 132 participants
  Moderate

5‐ASA vs placebo

5‐ASA showed no clear difference in adverse events compared with placebo (low certainty).

• Oral 5‐aminosalicylic acid for maintenance of medically‐induced remission in Crohn's disease 2016 · Cochrane Headline outcomes only
  RR 1.05 [0.95, 1.17]
  10 studies · 1814 participants
  Low

5‐ASA vs placebo

5‐ASA showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).

• Oral 5‐aminosalicylic acid for maintenance of medically‐induced remission in Crohn's disease 2016 · Cochrane Headline outcomes only
  RR 1.11 [0.88, 1.38]
  10 studies · 1833 participants
  Low

5‐ASA vs placebo

5‐ASA showed no clear difference in serious adverse events compared with placebo (low certainty).

• Oral 5‐aminosalicylic acid for maintenance of medically‐induced remission in Crohn's disease 2016 · Cochrane Headline outcomes only
  RR 1.43 [0.24, 8.44]
  3 studies · 576 participants
  Low

Intervention not reported

It is very uncertain whether the intervention changes number of participants receiving transfusion with allogeneic blood:… (very low certainty).

• Antifibrinolytic agents for reducing blood loss in scoliosis surgery in children 2016 · Cochrane Headline outcomes only
  RR 0.11 [0.01, 1.73]
  1 study · 43 participants
  Very low

Intervention not reported

• Antifibrinolytic agents for reducing blood loss in scoliosis surgery in children 2016 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 87 participants
  Low

Intervention not reported

• Antifibrinolytic agents for reducing blood loss in scoliosis surgery in children 2016 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 84 participants
  Low

Intervention not reported

• Antifibrinolytic agents for reducing blood loss in scoliosis surgery in children 2016 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 87 participants
  Low

Intervention not reported

• Antifibrinolytic agents for reducing blood loss in scoliosis surgery in children 2016 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 84 participants
  Low

Intervention not reported

It is very uncertain whether the intervention changes number of participants receiving blood transfusion: aprotinin vs… (very low certainty).

• Antifibrinolytic agents for reducing blood loss in scoliosis surgery in children 2016 · Cochrane Headline outcomes only
  RR 0.75 [0.44, 1.27]
  1 study · 43 participants
  Very low

Intervention not reported

It is very uncertain whether the intervention changes number of participants receiving blood transfusion: tranexamic acid… (very low certainty).

• Antifibrinolytic agents for reducing blood loss in scoliosis surgery in children 2016 · Cochrane Headline outcomes only
  RR 0.85 [0.56, 1.3]
  1 study · 44 participants
  Very low

IRI with fluoropyrimidines vs single agent IRI

IRI with fluoropyrimidines showed no clear difference in overall survival (Death) compared with single agent IRI (low certainty).

• Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and… 2016 · Cochrane Headline outcomes only
  HR 0.91 [0.81, 1.02]
  5 studies · 1728 participants
  Low

IRI with fluoropyrimidines vs single agent IRI

IRI with fluoropyrimidines probably leads to lower progression‐free survival (Disease progression) compared with single agent IRI (moderate certainty).

• Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and… 2016 · Cochrane Headline outcomes only
  HR 0.68 [0.53, 0.83]
  3 studies · 600 participants
  Moderate

IRI with fluoropyrimidines vs single agent IRI

IRI with fluoropyrimidines probably leads to lower grade 3/4 diarrhea compared with single agent IRI (moderate certainty).

• Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and… 2016 · Cochrane Headline outcomes only
  RR 0.66 [0.51, 0.85]
  5 studies · 1179 participants
  Moderate

IRI with fluoropyrimidines vs single agent IRI

IRI with fluoropyrimidines showed no clear difference in grade 3/4 nausea compared with single agent IRI (low certainty).

• Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and… 2016 · Cochrane Headline outcomes only
  RR 0.33 [0.07, 1.58]
  3 studies · 209 participants
  Low

Sulfasalazine vs placebo

Sulfasalazine showed no clear difference in induction of remission (CDAI <150), therapeutic response (VHI… compared with placebo (low certainty).

• Aminosalicylates for induction of remission or response in Crohn's disease 2016 · Cochrane Headline outcomes only
  RR 1.52 [0.95, 2.43]
  3 studies · 289 participants
  Low

Azo‐bonded and delayed‐release mesalamine (2 ‐ 3.2 g/day) vs placebo

It is very uncertain whether azo‐bonded and delayed‐release mesalamine (2 ‐ 3.2 g/day) changes induction of remission or clinical improvement ‐ Asacol (3.2 g/day) compared with placebo (very low certainty).

• Aminosalicylates for induction of remission or response in Crohn's disease 2016 · Cochrane Headline outcomes only
  RR 2.7 [1.06, 6.88]
  1 study · 38 participants
  Very low
• Aminosalicylates for induction of remission or response in Crohn's disease 2016 · Cochrane Headline outcomes only
  RR 0.36 [0.18, 0.71]
  1 study · 91 participants
  Very low

Azo‐bonded and delayed‐release mesalamine (2 ‐ 3.2 g/day) vs placebo

It is very uncertain whether azo‐bonded and delayed‐release mesalamine (2 ‐ 3.2 g/day) changes induction of remission (CDAI < 150 + decrease >=70) ‐ Asacol (3.2… compared with placebo (very low certainty).

• Aminosalicylates for induction of remission or response in Crohn's disease 2016 · Cochrane Headline outcomes only
  RR 2.03 [0.75, 5.45]
  1 study · 38 participants
  Very low

Delayed‐release mesalamine (3 ‐ 4.5 g/day) vs corticosteroids

Delayed‐release mesalamine (3 ‐ 4.5 g/day) showed no clear difference in induction of remission (CDAI < or =150 with or without decrease of… compared with corticosteroids (moderate certainty).

• Aminosalicylates for induction of remission or response in Crohn's disease 2016 · Cochrane Headline outcomes only
  RR 1.04 [0.79, 1.36]
  3 studies · 178 participants
  Moderate
• Aminosalicylates for induction of remission or response in Crohn's disease 2016 · Cochrane Headline outcomes only
  RR 0.95 [0.49, 1.85]
  1 study · 50 participants
  Low
• Aminosalicylates for induction of remission or response in Crohn's disease 2016 · Cochrane Headline outcomes only
  RR 1 [0.61, 1.64]
  1 study · 50 participants
  Moderate